HUP0203896A2 - Helyettesítet 8-arilkinolin-foszfodiészteráz-4-inhibitorok és alkalmazásuk - Google Patents
Helyettesítet 8-arilkinolin-foszfodiészteráz-4-inhibitorok és alkalmazásukInfo
- Publication number
- HUP0203896A2 HUP0203896A2 HU0203896A HUP0203896A HUP0203896A2 HU P0203896 A2 HUP0203896 A2 HU P0203896A2 HU 0203896 A HU0203896 A HU 0203896A HU P0203896 A HUP0203896 A HU P0203896A HU P0203896 A2 HUP0203896 A2 HU P0203896A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- group
- heteroaryl
- aryl
- son
- Prior art date
Links
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- -1 carbonyl- Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 125000005429 oxyalkyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát az 1. általános képletű vegyület vagy annakgyógyászatilag elfogadható sója - a képletben S1,S2, és S3 jelentésehidrogén-, halogénatom, OH-, NO2 -, CN-, alkil- vagy alkoxicsoport,ahol az alkil- és alkoxicsoportok adott esetben 1-5 szubsztituensselhelyettesítettek, ahol szubsztituensek halogénatom vagy OH-csoport; R1jelentése hidrogén-, halogénatom, hidroxil-, karbonil-, alkil-,cikloalkil-, alkenil-, alkoxi-, aril-, heteroaril-, CN-, heterociklo-alkil-, amino-, alkilamino-, dialkil-amino-, alkoxi- alkil-, -C(O)NH-(aril)-, C(O)NH-(heteroaril)-, SOnNH-(aril)-, SOnNH-(heteroaril)-,SOnNH- (alkil)-, -C(O)N-alkil)-(alkil)-, -NH-SOn(alkil)-, SOn(alkil)-,(alkil)-O-C(CN)-dialkilamino- vagy (alkil)-SOn-(alkil)-csoport, ahol acsoportok bármelyike adott esetben 1-5 szubsztituensselhelyettesített; A jelentése CH-, C-észter- vagy C-R4-csoport; R2 és R3jelentése egymástól függetlenül aril-, heteroarilcsoport, hidrogén-,halogénatom, CN-, alkil-, heterociklo-(alkil)-, alkoxi-, karboxil-,karbamoil-, C(O)OH, (alkil)-SOn-alkil)-, -C(O)N(alkil)-(alkil)- vagyalkil-acilamino-csoport, ahol bármely csoport adott esetben 1-5szubsztituenssel helyettesített; R2 és R3 közül egynek adott esetbenhelyettesített aril- vagy heteroarilcsoportnak kell lennie; amikor R2és R3 jelentése egyaránt aril- vagy heteroarilcsoport, akkor R2 és R3adott esetben egy tio-, oxi- vagy 1-4 szénatomos alkil-híddal lehetkapcsolva, így kondenzált háromgyűrűs rendszert képez; R4 jelentésearil-, alkil-, heteroaril-, CN-, karbonil-, karbamoil-, (alkil)-SOn-(alkil)-, -C(O)N-(alkil)-(alkil)- vagy alkil-acilamino-csoport, ahol acsoportok bármelyike adott esetben 1-5 szubsztituensselhelyettesített; n értéke függetlenül 0, 1 vagy 2; és R2 vagy R3 adottesetben R4 csoporthoz kapcsolódhat egy kötéssel, így egy gyűrűtképeznek. A találmány tárgya továbbá az 1. általános képletű vegyületalkalmazása - többek között - asztma, krónikus bronchitis kezelésérevagy megelőzésére szolgáló in vivo képződő gyógyszerkészítményelőállítására. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17152299P | 1999-12-22 | 1999-12-22 | |
| PCT/CA2000/001559 WO2001046151A1 (en) | 1999-12-22 | 2000-12-20 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0203896A2 true HUP0203896A2 (hu) | 2003-04-28 |
| HUP0203896A3 HUP0203896A3 (en) | 2003-05-28 |
Family
ID=22624050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203896A HUP0203896A3 (en) | 1999-12-22 | 2000-12-20 | Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1244628A1 (hu) |
| JP (1) | JP3782011B2 (hu) |
| KR (1) | KR20020082839A (hu) |
| CN (1) | CN1221534C (hu) |
| AR (1) | AR029214A1 (hu) |
| AU (1) | AU778531B2 (hu) |
| BG (1) | BG65403B1 (hu) |
| BR (1) | BR0016651A (hu) |
| CA (1) | CA2393749C (hu) |
| CO (1) | CO5261613A1 (hu) |
| CZ (1) | CZ20022171A3 (hu) |
| DZ (1) | DZ3244A1 (hu) |
| EA (1) | EA004747B1 (hu) |
| EE (1) | EE200200342A (hu) |
| GE (1) | GEP20053626B (hu) |
| HK (1) | HK1057560A1 (hu) |
| HR (1) | HRP20020545A2 (hu) |
| HU (1) | HUP0203896A3 (hu) |
| IL (1) | IL150114A0 (hu) |
| IS (1) | IS6413A (hu) |
| MX (1) | MXPA02006329A (hu) |
| MY (1) | MY134008A (hu) |
| NO (1) | NO20023013L (hu) |
| NZ (1) | NZ520258A (hu) |
| PE (1) | PE20010989A1 (hu) |
| PL (1) | PL355752A1 (hu) |
| SK (1) | SK8972002A3 (hu) |
| TW (1) | TWI280240B (hu) |
| UA (1) | UA74815C2 (hu) |
| WO (1) | WO2001046151A1 (hu) |
| YU (1) | YU47102A (hu) |
| ZA (1) | ZA200204862B (hu) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| NZ526143A (en) * | 2000-12-20 | 2004-05-28 | Merck & Co Inc | Process for making substituted 8-arylquinolinium benzenesulfonate |
| AU2002344885C1 (en) * | 2001-06-27 | 2006-11-09 | Merck Frosst Canada Ltd | Substituted 8-arylquinoline PDE4 Inhibitors |
| WO2003010137A1 (en) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Preparation of sulfonyl quinoline |
| HUP0500078A3 (en) * | 2001-09-19 | 2010-07-28 | Nycomed Gmbh | Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist |
| CA2479069A1 (en) * | 2002-03-18 | 2003-09-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
| JP2006519874A (ja) * | 2003-03-05 | 2006-08-31 | セルジーン・コーポレーション | ジフェニルエチレン化合物およびその使用 |
| EP1732900A4 (en) * | 2004-03-25 | 2007-12-12 | Synta Pharmaceuticals Corp | ACRYLONITRILE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF INFLAMMATION AND IMMUNE DISORDERS |
| CA2608158A1 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
| ATE535244T1 (de) | 2006-07-05 | 2011-12-15 | Nycomed Gmbh | Kombination aus atorvastatin mit einem phosphodiesterase-4-hemmer zur behandlung von entzündlichen lungenerkrankungen |
| JP5280357B2 (ja) * | 2006-07-07 | 2013-09-04 | スティーブン・ピー・ガベック | Ｐｄｅ４の二環式ヘテロアリール阻害剤 |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| AU2008215948A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of AD and related conditions |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| WO2011099305A1 (en) | 2010-02-12 | 2011-08-18 | Raqualia Pharma Inc. | 5-ht4 receptor agonists for the treatment of dementia |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| WO2013054153A1 (en) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nutlin compounds for use in he treatment of pulmonary hypertension |
| CN111406051A (zh) * | 2017-09-03 | 2020-07-10 | 安吉昂生物医药公司 | 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| US6245774B1 (en) * | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| JPH11209350A (ja) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
-
2000
- 2000-12-19 MY MYPI20005965A patent/MY134008A/en unknown
- 2000-12-20 CA CA002393749A patent/CA2393749C/en not_active Expired - Fee Related
- 2000-12-20 EE EEP200200342A patent/EE200200342A/xx unknown
- 2000-12-20 CN CNB00818951XA patent/CN1221534C/zh not_active Expired - Fee Related
- 2000-12-20 CO CO00096650A patent/CO5261613A1/es not_active Application Discontinuation
- 2000-12-20 GE GE4903A patent/GEP20053626B/en unknown
- 2000-12-20 SK SK897-2002A patent/SK8972002A3/sk not_active Application Discontinuation
- 2000-12-20 IL IL15011400A patent/IL150114A0/xx unknown
- 2000-12-20 MX MXPA02006329A patent/MXPA02006329A/es not_active Application Discontinuation
- 2000-12-20 UA UA2002076108A patent/UA74815C2/uk unknown
- 2000-12-20 HU HU0203896A patent/HUP0203896A3/hu unknown
- 2000-12-20 YU YU47102A patent/YU47102A/sh unknown
- 2000-12-20 EP EP00986937A patent/EP1244628A1/en not_active Withdrawn
- 2000-12-20 BR BR0016651-0A patent/BR0016651A/pt not_active IP Right Cessation
- 2000-12-20 KR KR1020027008079A patent/KR20020082839A/ko not_active Application Discontinuation
- 2000-12-20 WO PCT/CA2000/001559 patent/WO2001046151A1/en active IP Right Grant
- 2000-12-20 CZ CZ20022171A patent/CZ20022171A3/cs unknown
- 2000-12-20 NZ NZ520258A patent/NZ520258A/en unknown
- 2000-12-20 PL PL00355752A patent/PL355752A1/xx not_active IP Right Cessation
- 2000-12-20 AU AU23362/01A patent/AU778531B2/en not_active Ceased
- 2000-12-20 DZ DZ003244A patent/DZ3244A1/fr active
- 2000-12-20 JP JP2001547062A patent/JP3782011B2/ja not_active Expired - Fee Related
- 2000-12-20 EA EA200200702A patent/EA004747B1/ru not_active IP Right Cessation
- 2000-12-21 TW TW089127506A patent/TWI280240B/zh not_active IP Right Cessation
- 2000-12-21 AR ARP000106867A patent/AR029214A1/es not_active Application Discontinuation
- 2000-12-22 PE PE2000001396A patent/PE20010989A1/es not_active Application Discontinuation
-
2002
- 2002-06-11 IS IS6413A patent/IS6413A/is unknown
- 2002-06-18 ZA ZA200204862A patent/ZA200204862B/en unknown
- 2002-06-19 BG BG106840A patent/BG65403B1/bg unknown
- 2002-06-21 NO NO20023013A patent/NO20023013L/no unknown
- 2002-06-21 HR HR20020545A patent/HRP20020545A2/hr not_active Application Discontinuation
-
2004
- 2004-01-26 HK HK04100511A patent/HK1057560A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203896A2 (hu) | Helyettesítet 8-arilkinolin-foszfodiészteráz-4-inhibitorok és alkalmazásuk | |
| CA2432085A1 (en) | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands | |
| MY118163A (en) | Aryl fused azapolycyclic compounds | |
| BG104138A (en) | 2-aminopyridines containing substituents with condensed rings as nos inhibitors | |
| CA2134964A1 (en) | Bridged Aza-Bicyclic Derivatives as Substance P Antagonists | |
| AP2002002637A0 (en) | Novel piperazine | |
| CA2401229A1 (en) | Aryl fused azapolycyclic compounds | |
| HUP0003309A2 (hu) | Imidazolilcsoportot tartalmazó gyűrűs acetálok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| DE60140456D1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| GB9914486D0 (en) | Medicaments | |
| CA2123403A1 (en) | Acyclic ethylenediamine derivatives as substance p receptor antagonists | |
| DE69223965T2 (de) | Anticonvulsives aminosäurederivat | |
| NO985711D0 (no) | Farmas°ytikum for behandling av neurologiske og neuropsykiatriske mangler | |
| HUP0103366A2 (hu) | Citokin inhibítorként használható amidszármazékok | |
| DE69705300D1 (de) | Cyclopropylalkansäurederivate | |
| EA200200119A1 (ru) | β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ | |
| TR199801782T2 (xx) | Kinoksalindionlar | |
| NO20062599L (no) | Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav | |
| HUP0301458A2 (hu) | Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása | |
| AP2001002306A0 (en) | Bridged piperazine derivatives. | |
| HUP9903168A2 (hu) | Kondenzált piridazinszármazékokat tartalmazó, merevedési rendellenességek kezelésére alkalmas gyógyszerek | |
| YU64400A (sh) | Aril fuzirana azapoliciklična jedinjenja | |
| DE69434652D1 (de) | Antikonvulsive pseudofructopyranose sulfamate | |
| CA2092306A1 (en) | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity | |
| BG104243A (en) | Method for the synthesis of quinoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: MERCK FROSST CANADA LTD., CA Free format text: FORMER OWNER(S): MERCK FROSST CANADA & CO., CA |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |